The clinical studies of crizotinib and ceritinib for patients with refractory or relapsed ALK-driven neuroblastoma showed responses that were limited mainly to tumors harboring an ALK R1275 mutation with no activity in tumors harboring an F1174 mutation12,31. This evidence concerns the gene ALK and neuroblastoma.